Benzyl alcohol
- Generic Name
- Benzyl alcohol
- Brand Names
- Cipro, Cipro HC, Itch-X, Ivy-dry Cream, Ulesfia, Zilactin Cold Sore
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8O
- CAS Number
- 100-51-6
- Unique Ingredient Identifier
- LKG8494WBH
- Indication
Ulesfia (benzyl alcohol) lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Ulesfia Lotion does not have ovicidal activity.
- Associated Conditions
- Cold Sore, Fever blister, Head Lice Infestation, Insect Bites, Oral Pain, Skin Irritation, Sunburn, Abrasions, Minor burns, Superficial Wounds
Immature Granulocyte [IG] Count and Percentage for Medical Treatment of Uncomplicated Acute Appendicitis
Completed
- Conditions
- Acute Appendicitis Without PeritonitisMedical Emergencies
- Interventions
- Procedure: appendectomy (open or laparascopic)
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Kahramanmaras Sutcu Imam University
- Target Recruit Count
- 64
- Registration Number
- NCT04462588
- Locations
- 🇹🇷
Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey
Bioequivalence Study for Benzyl Alcohol Lotion 5%.
Phase 3
Completed
- Conditions
- Head Lice
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Akorn, Inc.
- Target Recruit Count
- 239
- Registration Number
- NCT02624843
- Locations
- 🇺🇸
Axis Clinical Trials, Los Angeles, California, United States
🇺🇸South Florida Family Health and Research Centers (Lice Source Services Inc), Plantation, Florida, United States
Special Drug Use Investigation of Ciproxan Injection in Pediatrics
Completed
- Conditions
- Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 48
- Registration Number
- NCT02555059
Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2012-09-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 704
- Registration Number
- NCT01690559
Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder
Phase 1
Completed
- Conditions
- InfectionPulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT01168895
A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension
Phase 3
Completed
- Conditions
- Otitis Externa
- Interventions
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- Farmoquimica S.A.
- Target Recruit Count
- 224
- Registration Number
- NCT00980876
- Locations
- 🇧🇷
Clínica Quiron, Campinas, São Paulo, Brazil
Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections
Phase 4
Completed
- Conditions
- Urinary Tract Infection
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 276
- Registration Number
- NCT00676533
Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections
Phase 3
Completed
- Conditions
- Urinary Tract Infection
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 212
- Registration Number
- NCT00668122
Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 35
- Registration Number
- NCT00650351
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 36
- Registration Number
- NCT00649155
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath